Format

Send to

Choose Destination
Mol Aspects Med. 2019 Jun 14. pii: S0098-2997(19)30009-3. doi: 10.1016/j.mam.2019.06.002. [Epub ahead of print]

Circulating biomarkers for early detection and clinical management of colorectal cancer.

Author information

1
Gastrointestinal & Pancreatic Oncology Group, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) / Hospital Clínic of Barcelona/ Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
2
Institute of Experimental Medicine of the Czech Academy of Sciences and Institute of Biology and Medical Genetics, First Medical Faculty, Charles University, Prague, Czech Republic.
3
Experimental Surgical Oncology, General, Visceral and Pediatric Surgery, University Hospital and Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
4
Department of Molecular Oncology, Institute for Cancer Research, K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital-Norwegian Radium Hospital, Oslo, Norway.
5
Department of Clinical Genetics, Karolinska University Hospital and Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
6
Molecular Oncology Laboratory, Hospital Clinico San Carlos, IdISSC, CIBERONC, Madrid, Spain.
7
Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
8
Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz and Christian Doppler Laboratory for Liquid Biopsies for early Detection of Cancer, Austria.
9
Gastrointestinal & Pancreatic Oncology Group, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) / Hospital Clínic of Barcelona/ Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain. Electronic address: meritxell.gironella@ciberehd.org.

Abstract

New non-invasive approaches that can complement and improve on current strategies for colorectal cancer (CRC) screening and management are urgently needed. A growing number of publications have documented that components of tumors, which are shed into the circulation, can be detected in the form of liquid biopsies and can be used to detect CRC at early stages, to predict response to certain therapies and to detect CRC recurrence in a minimally invasive way. The analysis of circulating tumor DNA (ctDNA), tumor-derived cells (CTC, circulating tumor cells) or circulating microRNA (miRNA) in blood and other body fluids, have a great potential to improve different aspects of CRC management. The challenge now is to find which types of components, biofluids and detection methods would be the most suitable to be applied in the different steps of CRC detection and treatment. This chapter will provide an up to date review on ctDNA, CTCs and circulating miRNAs as new biomarkers for CRC, either for clinical management or early detection, highlighting their advantages and limitations.

KEYWORDS:

Cell-free DNA; Circulating tumor cells (CTC); Liquid biopsy; MicroRNA; Prognosis; Screening

PMID:
31189073
DOI:
10.1016/j.mam.2019.06.002
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for Norwegian BIBSYS system
Loading ...
Support Center